Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy.
We previously reported the effectiveness of trans-aconitic acid (TAA) as an antileishmanial compound. Inhibitory effects of TAA along with other antileishmanial compounds on transformation and in vitro multiplication in macrophage cultures of Leishmania donovani have been assessed. The efficacy of TAA in combined chemotherapy of experimental visceral leishmaniasis has also been evaluated along with those of commonly used antileishmanial compounds such as sodium stibogluconate, pentamidine, and allopurinol. TAA (2 mM) inhibited transformation of L. donovani amastigotes to promastigotes by 95.2%, whereas in combination with pentamidine (5 micrograms/ml), allopurinol (10 micrograms/ml), and sodium stibogluconate (50 micrograms of Sb per ml), it inhibited transformation by about 100, 99, and 98.5%, respectively. Sodium stibogluconate (20 micrograms of Sb per ml), pentamidine (2 micrograms/ml), and allopurinol (5 micrograms/ml) suppressed the amastigote burden in peritoneal macrophage cultures from BALB/c mice by 32.6, 56.1, and 46.3%, respectively. When these three drugs were used along with TAA (5 mM), the parasite loads were reduced by 100, 100, and 88.1%, respectively. TAA (5 mM) alone suppressed the amastigote burden by 59.5%. In experimental visceral leishmaniasis in hamsters (1-month model), TAA at a dose of 200 mg/kg of body weight per day suppressed the spleen parasite load by 73.5%, and TAA in combination with sodium stibogluconate (50 mg of Sb per kg per day), pentamidine (8 mg/kg/day), and allopurinol (15 mg/kg/day) inhibited the spleen parasite load by 98, 98.9, and 97%, respectively. Individually, these three drugs inhibited the parasite load by 35, 20, and 22%, respectively. TAA (400 mg/kg/day) inhibited the spleen parasite load by 99.8%, but an inhibitory effect of approximately 100% was noted when TAA was supplemented with an antileishmanial drug. TAA was administered in experimental animals through oral, intraperitoneal, and intramuscular routes; the intramuscular route was most effective.
Kar
S
S
Leishmania Group, Indian Institute of Chemical Biology, Calcutta.
Kar
K
K
Bhattacharya
P K
PK
Ghosh
D K
DK
D000156:Aconitic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D002478:Cells, Cultured; D006224:Cricetinae; D004359:Drug Therapy, Combination; D066298:In Vitro Techniques; D007893:Leishmania donovani / Q000187:drug effects / Q000254:growth & development; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D008099:Liver / Q000469:parasitology; D008264:Macrophages / Q000187:drug effects / Q000469:parasitology; D008647:Mesocricetus; D051379:Mice; D008807:Mice, Inbred BALB C; D010419:Pentamidine / Q000627:therapeutic use; D013154:Spleen / Q000469:parasitology; D013237:Stereoisomerism
D000493:Allopurinol; D010419:Pentamidine; D000156:Aconitic Acid; D000967:Antimony Sodium Gluconate